ATE439372T1 - Nukleinsäuren und proteine von gruppen a und b- streptokokken - Google Patents

Nukleinsäuren und proteine von gruppen a und b- streptokokken

Info

Publication number
ATE439372T1
ATE439372T1 AT01982584T AT01982584T ATE439372T1 AT E439372 T1 ATE439372 T1 AT E439372T1 AT 01982584 T AT01982584 T AT 01982584T AT 01982584 T AT01982584 T AT 01982584T AT E439372 T1 ATE439372 T1 AT E439372T1
Authority
AT
Austria
Prior art keywords
proteins
group
streptococcus
streptococics
nucleic acids
Prior art date
Application number
AT01982584T
Other languages
English (en)
Inventor
John Telford
Vega Masignani
Y Ros Immaculada Margarit
Guido Grandi
Claire Fraser
Herve Tettelin
Original Assignee
Novartis Vaccines & Diagnostic
Craig J Venter Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0026333A external-priority patent/GB0026333D0/en
Priority claimed from GB0028727A external-priority patent/GB0028727D0/en
Priority claimed from GB0105640A external-priority patent/GB0105640D0/en
Application filed by Novartis Vaccines & Diagnostic, Craig J Venter Inst Inc filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE439372T1 publication Critical patent/ATE439372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
AT01982584T 2000-10-27 2001-10-29 Nukleinsäuren und proteine von gruppen a und b- streptokokken ATE439372T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0026333A GB0026333D0 (en) 2000-10-27 2000-10-27 Streptococcus antigens
GB0028727A GB0028727D0 (en) 2000-11-24 2000-11-24 Streptococcus antigens
GB0105640A GB0105640D0 (en) 2001-03-07 2001-03-07 Streptococcus proteins
PCT/GB2001/004789 WO2002034771A2 (en) 2000-10-27 2001-10-29 Nucleic acids and proteins from streptococcus groups a & b

Publications (1)

Publication Number Publication Date
ATE439372T1 true ATE439372T1 (de) 2009-08-15

Family

ID=27255953

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982584T ATE439372T1 (de) 2000-10-27 2001-10-29 Nukleinsäuren und proteine von gruppen a und b- streptokokken

Country Status (16)

Country Link
US (10) US7939087B2 (de)
EP (10) EP2277895B1 (de)
JP (5) JP4254931B1 (de)
AT (1) ATE439372T1 (de)
AU (2) AU2002214127B2 (de)
CA (2) CA2881568C (de)
CY (1) CY1110698T1 (de)
DE (1) DE60139563D1 (de)
DK (1) DK1328543T3 (de)
ES (1) ES2330083T3 (de)
IL (5) IL154853A0 (de)
MX (2) MX357775B (de)
NZ (6) NZ524888A (de)
SG (1) SG165981A1 (de)
WO (1) WO2002034771A2 (de)
ZA (1) ZA200302739B (de)

Families Citing this family (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
EA004444B1 (ru) 1998-12-22 2004-04-29 Майкросайенс Лимитед Гены и белки и их применение
US7491402B2 (en) * 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
EP1905834A3 (de) * 1999-12-23 2008-07-23 Vmax Limited Virulenzgene, Proteine und deren Verwendung
EP1360324A2 (de) 2000-08-31 2003-11-12 Mayo Foundation For Medical Education And Research Nachweis von varicella-zoster-virus
ATE439372T1 (de) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
US7595057B2 (en) 2000-12-21 2009-09-29 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
US7691571B2 (en) 2001-01-31 2010-04-06 Mayo Foundation For Medical Education And Research Detection of bordetella
ATE465272T1 (de) 2001-01-31 2010-05-15 Mayo Foundation Nachweis von herpex-simplex-virus
BRPI0207447B1 (pt) 2001-02-21 2015-09-22 Id Biomedical Corp polipeptídeo recombinante isolado, seu uso e processo de produção, vetor de expressão, célula hospedeira microbiana transgênica, composição farmacêutica, uso da dita composição, métodos de detecção e kit
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
JP2004533236A (ja) 2001-04-13 2004-11-04 ワイエス 化膿性連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｙｏｇｅｎｅｓ）の表面タンパク質
AU2008207670B2 (en) * 2001-04-13 2011-06-16 Wyeth Surface proteins of streptococcus pyogenes
JP2005503774A (ja) * 2001-05-02 2005-02-10 シャイアー バイオケム インコーポレイテッド グループｂストレプトコッカスの抗原および対応ｄｎａフラグメント
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003004650A2 (en) 2001-07-06 2003-01-16 Shire Biochem Inc. Group b streptococcus antigens and corresponding dna fragments
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP2168596B1 (de) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen Chlamydia trachomatis
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
JP4489582B2 (ja) * 2002-05-28 2010-06-23 オムリクス・バイオフアーマシユーチカルズ・インコーポレーテツド 抗イディオタイプ抗体を得る方法
WO2004007725A1 (en) * 2002-07-15 2004-01-22 Id Biomedical Corporation Polypeptide of streptococcus pyogenes
AU2003250684A1 (en) * 2002-07-31 2004-02-16 Affinium Pharmaceuticals, Inc. Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
US7601804B2 (en) * 2002-08-12 2009-10-13 Intervet International B.V. Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
DE10239629A1 (de) * 2002-08-23 2004-04-08 Idt Impfstoffwerk Dessau-Tornau Gmbh Nicht-rekombinate Subunit-Vakzine gegen Streptococcus suis-Infektionen des Schweines
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
US20040081646A1 (en) * 2002-08-29 2004-04-29 Engler Jeffrey A. Group B Streptococcal phage lysin
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004041157A2 (en) * 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
US7074598B2 (en) 2002-09-25 2006-07-11 Mayo Foundation For Medical Education And Research Detection of vancomycin-resistant enterococcus spp.
US7365176B2 (en) 2002-09-26 2008-04-29 Mayo Foundation For Medical Education And Research Detection of Epstein-Barr virus
AU2003277312A1 (en) * 2002-10-08 2004-05-04 Indranil Biswas Methods, probes, and kits for detecting group a streptococcus
EP2314603A3 (de) * 2002-10-15 2011-05-18 Intercell AG Bindungdsfaktoren von Gruppe B-Streptococcus, dafür kodierende Nukleinsäuren und Verwendungen davon
MXPA05004528A (es) 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DE10300335B4 (de) * 2003-01-09 2008-06-26 Iep Gmbh Oxidoreduktase
EP1601770B1 (de) * 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigene
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP2333114A1 (de) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae Antigene
EP1620460A2 (de) * 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae-antigene i + ii
CN102304527A (zh) * 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
EP1641818B1 (de) * 2003-07-04 2008-12-03 Affibody AB Polypeptide mit bindungsaffinität für her2
JP4875490B2 (ja) * 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
CA2535863A1 (en) * 2003-08-15 2005-02-24 Id Biomedical Corporation Polypeptides of streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
CA2537742C (en) * 2003-09-15 2014-07-22 Chiron Corporation Immunogenic compositions for streptococcus agalactiae
ES2362749T3 (es) * 2003-09-15 2011-07-12 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para streptococcus agalactiae.
US7427475B2 (en) * 2003-11-18 2008-09-23 Mayo Foundation For Medical Education And Research Detection of group B streptococcus
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
CA2571593C (en) * 2004-07-02 2015-04-21 Avi Biopharma, Inc. Antisense antibacterial method and compound
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
JP4481991B2 (ja) * 2004-08-17 2010-06-16 パナソニック株式会社 情報記録媒体、データ分別装置、データ再生装置及び記録方法
TWI377564B (en) * 2004-08-17 2012-11-21 Panasonic Corp Information storage medium and multiplexing device
GB0421465D0 (en) * 2004-09-27 2004-10-27 Chiron Srl Group A streptococcus protein
WO2006042027A2 (en) * 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2582661C (en) 2004-11-09 2015-08-11 Gen-Probe Incorporated Compositions and methods for detecting group a streptococci
WO2006069200A2 (en) * 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
AU2006206577B2 (en) 2005-01-21 2012-03-08 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US20060177859A1 (en) 2005-02-07 2006-08-10 Gen-Probe Incorporated Compositions and methods for detecting group B streptococci
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
JP5219803B2 (ja) * 2005-05-13 2013-06-26 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド グラム陽性菌の血清耐性因子
FR2886312B1 (fr) * 2005-05-26 2012-12-14 Abag Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a streptococcus pyogenes
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007016938A2 (en) * 2005-07-27 2007-02-15 Stichting Katholieke Universiteit Methods for diagnosing colon cancer and streptococcus bovis proteins for use in the method
EP1937304A2 (de) * 2005-08-24 2008-07-02 Novartis Vaccines and Diagnostics S.r.l. Zwitterionisation kapselförmiger saccharide
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1998800A2 (de) 2006-01-18 2008-12-10 University Of Chicago Zusammensetzungen und verfahren in verbindung mit stayphylokokken-bakterienproteinen
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US7588897B2 (en) 2006-05-12 2009-09-15 Gen-Probe Incorporated Compositions and methods to detect Enterococci nucleic acid
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
EP2319862A1 (de) 2006-07-07 2011-05-11 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US8343510B2 (en) 2007-01-12 2013-01-01 Intercell Ag Protective proteins of S. agalactiae, combinations thereof and methods of using the same
EP1953247A1 (de) * 2007-01-31 2008-08-06 GC Corporation Verfahren zur Messung der Anzahl oraler Streptokokken und in diesem Verfahren verwendetes PCR-Primer-Sondenset
EP2173902A4 (de) * 2007-07-03 2013-01-09 Mt Sinai Hospital Therapeutika und diagnostika für gruppe-a-streptokokken
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20110250221A1 (en) * 2007-08-24 2011-10-13 University Of Wollongong Group A Streptococcus Pharmaceutical Compositions and Methods Thereof
AU2013203022B2 (en) * 2007-09-12 2015-09-03 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
US9163077B2 (en) * 2007-12-19 2015-10-20 Rhovac Aps RhoC-based immunotherapy
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
EP2886551A3 (de) 2008-02-21 2015-09-23 Novartis AG Meningokokken-FHBP-Polypeptide
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
US8247170B2 (en) * 2008-05-16 2012-08-21 Medical Diagnostic Laboratories, Llc Detection of penicillin tolerance in Group B Streptococcus: single nucleotide polymorphisms in penicillin binding protein 4
US9545431B1 (en) * 2008-05-23 2017-01-17 The United States Of America, As Represented By The Secretary Of Agriculture Isolated recombinant cDNA
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
WO2009155476A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains
CN102264444B (zh) 2008-10-27 2015-08-05 诺华股份有限公司 纯化方法
CN107050442B (zh) * 2008-11-05 2022-09-13 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
CN102481349B (zh) 2009-01-12 2014-10-15 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
EP2443250B8 (de) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA Komplement-vermittelte antikörper-abhängige und opsonische bakterienassays mit hohem durchlauf
CN107126557A (zh) 2009-06-29 2017-09-05 健诺西生物科学公司 抗肺炎链球菌的疫苗和组合物
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
EP2493510B1 (de) 2009-09-30 2020-07-08 GlaxoSmithKline Biologicals SA Konjugation von kapselförmigen polysacchariden typ 5 und typ 8 aus staphylococcus aureus
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
KR102182663B1 (ko) 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
SI2591114T1 (sl) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
TR201908635T4 (tr) 2010-08-31 2019-07-22 Glaxosmithkline Biologicals Sa Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
WO2012031043A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP3520813B1 (de) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigenfreisetzungsplattformen
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
CA2858350A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012100234A1 (en) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
EP4014966A1 (de) 2011-07-06 2022-06-22 GlaxoSmithKline Biologicals S.A. Liposomen mit nützlichem n:p-verhältnis zur freisetzung von rna-molekülen
EP3854413A1 (de) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
EP2729178A1 (de) 2011-07-08 2014-05-14 Novartis AG Tyrosinverbindungsverfahren
EP2557424A1 (de) * 2011-08-11 2013-02-13 InGen Biosciences Verfahren zur Diagnose von Infektionen mit Streptococcus-, Enterococcus- und Pepstostreptococcus-Gattungen
SG11201400250UA (en) 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
EP2755683B1 (de) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Verfahren zur herstellung von saccharidprotein-glykokonjugaten
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス， インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
EP2788022B1 (de) 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Auf clostridium difficile-toxin basierender impfstoff
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013114363A2 (en) * 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
US9120111B2 (en) 2012-02-24 2015-09-01 Rain Bird Corporation Arc adjustable rotary sprinkler having full-circle operation and automatic matched precipitation
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
JP6542662B2 (ja) 2012-03-20 2019-07-10 サレプタ セラピューティクス， インコーポレイテッド オリゴヌクレオチドアナログのボロン酸結合体
GB201206366D0 (en) * 2012-04-11 2012-05-23 Absynth Biologics Ltd Bacterial vaccine
CN108671228A (zh) 2012-04-26 2018-10-19 诺华股份有限公司 抗原和抗原组合
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
RU2014151567A (ru) 2012-05-22 2016-07-10 Новартис Аг Конъюгат менингококка серогруппы х
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
US20150225734A1 (en) 2012-06-19 2015-08-13 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
US9156043B2 (en) 2012-07-13 2015-10-13 Rain Bird Corporation Arc adjustable rotary sprinkler with automatic matched precipitation
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
AR092896A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
EP3135765A1 (de) 2012-12-06 2017-03-01 Sigma-Aldrich Co. LLC Crispr-basierte genommodifizierung und -regulierung
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
EP3608308B1 (de) 2013-03-08 2021-07-21 Novartis AG Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen
SG11201507378UA (en) 2013-03-14 2015-10-29 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140273235A1 (en) * 2013-03-15 2014-09-18 Regents Of The University Of Minnesota ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
PL231394B1 (pl) * 2013-06-28 2019-02-28 Instytut Immunologii I Terapii Doświadczalnej Im Ludwika Hirszfelda Polskiej Akademii Nauk Test diagnostyczny zakażeń Streptococcus agalactiae
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
UA121200C2 (uk) * 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
US20150132263A1 (en) * 2013-11-11 2015-05-14 Radiant Genomics, Inc. Compositions and methods for targeted gene disruption in prokaryotes
AU2014359292B2 (en) 2013-12-03 2019-02-28 Swiss Tropical And Public Health Institute Proline-rich peptides protective against S. pneumoniae
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
EP3169309B1 (de) 2014-07-16 2023-05-10 Novartis AG Verfahren zur verkapselung einer nukleinsäure in einem lipidnanopartikelhost
GB201415602D0 (en) * 2014-09-03 2014-10-15 Moredun Res Inst Streptococcal antigens
CN107072946B (zh) 2014-09-05 2022-01-11 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
WO2016057954A2 (en) * 2014-10-10 2016-04-14 Board Of Regents Of The University Of Texas System Exogenous terminators for controlling fungal gene expression
US10420826B2 (en) * 2014-11-11 2019-09-24 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
AU2016225179C1 (en) 2015-02-23 2022-11-03 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
EP3262173A2 (de) 2015-02-23 2018-01-03 Crispr Therapeutics AG Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
EP3061826A1 (de) 2015-02-27 2016-08-31 Novartis AG Flavivirus-replikons
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
JP6914193B2 (ja) 2015-06-24 2021-08-04 Ｊｃｒファーマ株式会社 Ｂｄｎｆを含む融合蛋白質
KR20250073514A (ko) * 2015-06-24 2025-05-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
US9872188B2 (en) * 2015-07-28 2018-01-16 Futurewei Technologies, Inc. Adaptive filtering based network anomaly detection
WO2017031189A1 (en) * 2015-08-17 2017-02-23 Zuchem, Inc. Production of activated tdp-deoxysugars in recombinant microorganisms
CN105112350B (zh) * 2015-09-06 2019-02-01 西北农林科技大学 一种罗伊乳酸杆菌无抗性标记基因整合体系的建立方法及其应用
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
US12043843B2 (en) 2015-11-04 2024-07-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
WO2017078781A1 (en) * 2015-11-05 2017-05-11 Intel IP Corporation Long-term evolution (lte) and wireless local area network (wlan) aggregation (lwa) connection procedures
CA3007635A1 (en) 2015-12-07 2017-06-15 Zymergen Inc. Promoters from corynebacterium glutamicum
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
EP3439704A1 (de) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogene zusammensetzungen
JP2019519242A (ja) 2016-06-30 2019-07-11 ザイマージェン インコーポレイテッド 細菌ヘモグロビンライブラリーを生成するための方法およびその使用
WO2018005793A1 (en) 2016-06-30 2018-01-04 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN106169969B (zh) * 2016-08-31 2020-01-10 华为技术有限公司 建立虚拟专用网标签交换路径方法、相关设备和系统
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CA3052936A1 (en) 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein of bdnf and anti-transferrin receptor antibody
NZ752703A (en) 2016-12-26 2022-09-30 Japan Chem Res Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
EP3592381A1 (de) 2017-03-09 2020-01-15 President and Fellows of Harvard College Krebsimpfstoff
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CN108624516B (zh) * 2017-03-20 2022-08-26 华东理工大学 一种提高发酵细胞中的代谢产物量及制备idms标准品的方法
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
CN110785662A (zh) * 2017-04-26 2020-02-11 奥克兰联合服务有限公司 分析和治疗方法和组合物及其用途
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (de) 2017-08-30 2025-01-15 President and Fellows of Harvard College Hocheffiziente baseneditoren mit gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
SG11202005147WA (en) 2017-12-05 2020-06-29 Vertex Pharma Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
PL239045B1 (pl) * 2018-01-09 2021-11-02 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Epitop specyficzny dla zakaźnych Streptococcus agalactiae oraz sposób wykrywania zakażenia pacjenta szczepem Streptococcus agalactiae
WO2019150196A1 (en) 2018-02-05 2019-08-08 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US11268077B2 (en) 2018-02-05 2022-03-08 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
PL3752182T3 (pl) 2018-02-12 2024-11-25 Inimmune Corporation Ligandy receptorów toll-podobnych
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3820495A4 (de) 2018-07-09 2022-07-20 The Broad Institute Inc. Rna-programmierbare epigenetische rna-modifikatoren und deren verwendungen
CN109064036B (zh) * 2018-08-08 2021-07-06 武汉大学 面向管理领域的生态系统服务供需指数变化检测方法
EP3607967A1 (de) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modifizierte meningokokken fhbp polypeptide
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3942043A2 (de) 2019-03-19 2022-01-26 The Broad Institute, Inc. Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020229964A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
CN110489587B (zh) * 2019-07-31 2023-04-28 西安邮电大学 局部梯度方向三值模式的轮胎痕迹图像特征提取方法
US10948568B1 (en) * 2019-09-12 2021-03-16 Cypress Semiconductor Corporation Radar detection in a wireless LAN
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN111048833B (zh) * 2019-10-30 2022-04-26 深圳市卓能新能源股份有限公司 一种高电压电解液及高电压锂离子动力电池
WO2021222877A1 (en) * 2020-05-01 2021-11-04 Atex Technologies, Inc. Fray resistant structure
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
CN111518857B (zh) * 2020-06-11 2025-10-24 江苏海飞生物科技有限公司 酶法生产氨基葡萄糖盐及其提纯方法
WO2021250625A2 (en) * 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
KR20230118715A (ko) 2020-10-14 2023-08-11 조지 메이슨 리서치 파운데이션 인코포레이티드 이온화 가능 지질 및 이의 제조 및 사용 방법
CA3198876A1 (en) 2020-11-04 2022-05-12 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof
US12343748B2 (en) 2021-03-16 2025-07-01 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method
US20240285746A1 (en) * 2021-06-01 2024-08-29 The Regents Of The University Of California Protective vaccine antigen against streptococcal infection
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
EP4387597A1 (de) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Gefriertrocknung von lipidnanopartikeln (lnps) zur verkapselung von rna und formulierungen davon
EP4202043A1 (de) * 2021-12-22 2023-06-28 Technische Universität München Verfahren zur genetischen modifikation für cg-reiche mikroorganismen
CN116769845A (zh) * 2022-03-11 2023-09-19 中国科学院天津工业生物技术研究所 由甘油生成1,3-二羟基丙酮的方法及其应用
US12434252B2 (en) 2022-04-20 2025-10-07 Rain Bird Corporation Full-circle and part-circle rotor sprinkler
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
US12440855B2 (en) 2022-10-27 2025-10-14 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
US20260124157A1 (en) 2024-08-09 2026-05-07 Genvax Technologies, Inc. Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom

Family Cites Families (312)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386796A (en) 1942-08-05 1945-10-16 Bond Crown & Cork Co Extruding device
US3676548A (en) * 1970-09-18 1972-07-11 Lilly Co Eli Method of vaccinating swine against jowl abscess disease
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
FI821466A7 (fi) 1981-04-29 1982-10-30 Biogen Nv Bacillus-kloonausvektorit, yhdistelmä- DNA-molekyylit, niiden transformoimat Bacillus-isännät sekä menetelmätvieraiden DNA- sekvenssien ekspressiota varten sekä näiden koodaamien polypeptidien tuottamiseksi.
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
ATE67769T1 (de) * 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
US4659561A (en) * 1983-02-18 1987-04-21 The University Of Vermont And State Agricultural College Process for treating the oral cavity
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (de) 1983-10-03 1986-12-30 Genentech, Inc. Xenogeneisches Expressionskontrollsystem, Verfahren zu dessen Verwendung, dieses enthaltende Expressionsvektoren, mit denselben transformierte Zellen und daraus hergestellte heterolose Proteine
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
CA1260858A (en) 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
FI871919L (fi) 1986-05-02 1987-11-03 Gist Brocades Nv Sekretionssignalselektionsvektorer foer extracellulaer proteinsyntes hos bacillus-bakterier.
GB8618443D0 (en) * 1986-07-29 1986-09-03 Univ London Monoclonal antibodies
ATE247708T1 (de) 1986-10-02 2003-09-15 Massachusetts Inst Technology Verfahren zur regulierung der metabolischen stabilität von proteinen
WO1988002781A1 (en) * 1986-10-08 1988-04-21 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
CA1304020C (en) 1987-03-23 1992-06-23 Meher H. Irani High level expression in yeast
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
BR8807310A (pt) 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
SE456639B (sv) 1987-11-27 1988-10-24 Golf Comback Ab C O Wiklund Golftraeningsanordning innefattande ett hus med lintrumma
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
US5098827A (en) 1988-02-26 1992-03-24 The University Of Florida Novel bacterial markers for pathogenic group B streptococci
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
CH684094A5 (de) 1988-03-21 1994-07-15 Viagene Inc Rekombinante Retroviren.
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
GB8827038D0 (en) 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
US5354846A (en) 1988-11-18 1994-10-11 Michael Kehoe Streptolysin O antigen derivatives, its production and uses
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
MC2178A1 (fr) 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
GB2233977B (en) 1989-01-04 1993-03-31 Michael Kehoe Cytolytic streptolysin o mutants and uses
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0448650A4 (en) 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
EP0388186A1 (de) 1989-03-17 1990-09-19 E.I. Du Pont De Nemours And Company Externe Regulierung der Genexpression
EP0737750B1 (de) 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
ES2080153T3 (es) 1989-08-15 1996-02-01 Pasminco Australia Ltd Absorcion del vapor de cinc en el plomo fundido.
EP0487587A1 (de) 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US6737521B1 (en) 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
US5821088A (en) 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
WO1992005266A2 (en) 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992007945A1 (en) 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
DK0563278T3 (da) 1990-12-20 2000-08-21 Dana Farber Cancer Inst Inc Regulering af geneekspression med ioniserende stråling
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5378620A (en) 1991-08-30 1995-01-03 Beckman Instruments, Inc. Streptolysin O derivatives
US5391712A (en) 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08501686A (ja) 1992-09-25 1996-02-27 ローン−プーラン・ロレ・ソシエテ・アノニム 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター
WO1994011506A1 (en) 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
DE4240056A1 (de) 1992-11-28 1994-06-01 Boehringer Mannheim Gmbh Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
FI93733C (fi) * 1993-01-29 1995-05-26 Kaarina Tikkanen Streptococcus suis-bakteerin adhesiiniproteiini ja menetelmä sen valmistamiseksi
DE69433581T2 (de) 1993-02-01 2005-03-03 Beckman Coulter, Inc., Fullerton Mitogener Faktor, sein Gen und Verfahren zur dessen Mikrodetektion
US5348358A (en) 1993-02-22 1994-09-20 Selick David A Contact lens insertion tool
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
EP0695169B1 (de) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
DK0626452T3 (da) * 1993-05-17 2000-02-14 Akzo Nobel Nv Vaccine mod infektion af Streptococcus suis
CA2162271A1 (en) 1993-05-26 1994-12-08 Robert Kotin Fusion proteins containing adeno-associated virus rep protein and bacterial protein
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3644961B2 (ja) 1993-06-23 2005-05-11 ベックマン コールター インコーポレイテッド ストレプトコッカス・ピオゲネスから誘導された組換えｄｎアーゼｂ
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
CN1115414C (zh) 1993-07-13 2003-07-23 罗纳-布朗克罗莱尔股份有限公司 用于基因治疗的病毒载体
WO1995004139A1 (en) 1993-07-27 1995-02-09 The Wistar Institute Of Anatomy And Biology Modified dna virus vectors and uses therefor
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
EP0711829A3 (de) 1993-09-15 1997-07-09 Viagene Inc Rekombinanter Alphavirus Vektor
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
EP0723460A4 (de) 1993-10-01 1998-09-30 Us Health Gentherapie für das nervensystems
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
JP3002702B2 (ja) 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド 活性物質の制御放出を有する小胞
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5585098A (en) 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH07241786A (ja) 1994-03-08 1995-09-19 Fanuc Ltd 産業用ロボットの制御装置
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
WO1995029993A1 (en) 1994-04-28 1995-11-09 The University Of Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2723588B1 (fr) 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
ES2242191T3 (es) * 1994-09-14 2005-11-01 Baylor College Of Medicine Vacuna contra una infeccion por estreptococos del grupo a.
ATE296877T1 (de) 1994-10-07 2005-06-15 Univ Rockefeller Enzyme zur spaltung der verankerungsregion von oberflächenproteinen aus gram-positiven bakterien
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
AU5741996A (en) 1995-05-22 1996-12-11 Chiron Corporation Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US6346392B1 (en) * 1996-11-27 2002-02-12 Smithkline Beecham Corporation Polynucleotides encoding a novel glutamine transport ATP-binding protein
IES76925B2 (en) 1996-07-03 1997-11-19 Provost Subunit Vaccine for Streptococcus Equi
US5945278A (en) * 1996-07-08 1999-08-31 The Finnish National Public Health Institute Method and system for enhanced production of commercially important exoproteins in gram-positive bacteria
EP0821070A1 (de) 1996-07-22 1998-01-28 Carelli, Claude Marcel Henri Pit-1 Genpolymorphismus und Eigenschaftsauswahl in Tieren
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US6251433B1 (en) 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
CA2271720A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
JP2001510989A (ja) 1996-11-01 2001-08-07 スミスクライン・ビーチャム・コーポレイション 新規コーディング配列
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP0966304B1 (de) * 1997-02-20 2005-05-25 David S. Dime Ortsspezifische arzneimittel verabreichung
US7033765B1 (en) 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
EP0981625A2 (de) 1997-05-06 2000-03-01 Human Genome Sciences, Inc. Polynukleotide und sequenzen aus enterococcus faecalis
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
AU751009B2 (en) 1997-09-12 2002-08-08 University Of Tennessee Research Corporation, The Group A streptococcal vaccines
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
EP1037997A1 (de) 1997-09-26 2000-09-27 Medimmune, Inc. Lmb gen von streptococcus agalactiae
US6406883B1 (en) 1997-09-26 2002-06-18 Luetticken Rudolf Lmb gene of Streptococcus agalactiae
JP4402290B2 (ja) 1997-10-17 2010-01-20 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 新規な乳酸菌種
EP1900818A3 (de) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neissersche Antigene
JP2002536958A (ja) 1997-11-21 2002-11-05 ジェンセット Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
WO1999026969A1 (en) 1997-11-21 1999-06-03 University Of Otago Zoocin a immunity factor
EP2218732A1 (de) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Genomsequenz von Chlamydia trachomatis sowie Polypeptide, Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
JP2002508156A (ja) 1997-12-31 2002-03-19 ストレスジェン バイオテクノロジーズ コーポレイション Ｈｓｐ６０ファミリーのＳｔｒｅｐｔｏｃｏｃｃｕｓ熱ショックタンパク質
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
TR200002437T2 (tr) 1998-02-20 2000-11-21 Biochem Pharma Inc. B grubu streptococcus antijenleri.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9808327D0 (en) 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
EP2261347A3 (de) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
EP2180050B1 (de) * 1998-05-07 2016-04-20 Universite Libre De Bruxelles Auf Cytotoxinen basierendes biologisches Einschlusssystem
US6660520B2 (en) 1998-06-05 2003-12-09 Smithkline Beecham Corporation Nrde
CA2341268C (en) * 1998-07-22 2010-10-12 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Streptococcus suis vaccines and diagnostic tests
EP1100921B1 (de) 1998-07-27 2007-05-02 Sanofi Pasteur Limited Streptococcus pneumoniae proteine und nukleinsäuren
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
US6936252B2 (en) 1998-07-27 2005-08-30 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
EP1100920A2 (de) * 1998-07-27 2001-05-23 Microbial Technics Limited Nukleinsaüren und entsprechende proteine aus gruppe-b streptococcus
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
GB9828880D0 (en) * 1998-12-31 1999-02-17 Actinova Ltd Protein
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
CA2365523A1 (en) 1999-04-15 2000-10-26 The Regents Of The University Of California Identification of sortase gene
US7101692B2 (en) 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
WO2000078787A1 (en) 1999-06-21 2000-12-28 University Of Utah Research Foundation ISOLATED GENES FROM VIRULENT GROUP B $i(STREPTOCOCCUS AGALACTIAE)
US6833356B1 (en) 1999-08-25 2004-12-21 Medimmune, Inc. Pneumococcal protein homologs and fragments for vaccines
GB9921125D0 (en) * 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
WO2001022920A2 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
KR20020097200A (ko) 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 원핵세포에서의 필수유전자의 동정
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
WO2002004495A2 (en) 2000-07-06 2002-01-17 Shire Biochem Inc. Streptococcus pyogenes antigen
US6620585B1 (en) * 2000-08-02 2003-09-16 Elitra Pharmaceuticals, Inc. Use of ectoenzymes and secreted enzymes to monitor cellular proliferation
AU2001281168A1 (en) 2000-08-08 2002-02-18 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
FR2814754B1 (fr) * 2000-10-04 2005-09-09 Pasteur Institut Listeria innocua, genome et applications
WO2002057315A2 (en) 2000-10-10 2002-07-25 University Of Tennessee Research Corporation Streptococcal streptolysin s vaccines
US7160547B2 (en) 2000-10-10 2007-01-09 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
ATE439372T1 (de) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
JP2004533236A (ja) 2001-04-13 2004-11-04 ワイエス 化膿性連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｙｏｇｅｎｅｓ）の表面タンパク質
US20070128229A1 (en) 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
FR2824074A1 (fr) * 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
CA2881980A1 (en) 2001-05-18 2002-11-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
WO2003004650A2 (en) * 2001-07-06 2003-01-16 Shire Biochem Inc. Group b streptococcus antigens and corresponding dna fragments
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10136578B4 (de) * 2001-07-27 2005-05-04 Micronas Gmbh Verfahren zum Prüfen eines Chips mit einem Gehäuse und zum Bestücken einer Platine mit dem Gehäuse sowie Chip mit einem Gehäuse
US20060073530A1 (en) 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
CA2463008A1 (en) * 2001-10-26 2003-07-24 Id Biomedical Corporation Of Washington Efficient protein expression system
WO2003059252A2 (en) * 2001-12-21 2003-07-24 Children's Hospital & Regional Medical Center Use of a novel cell surface protease from group b streptococcus
ATE405289T1 (de) * 2001-12-27 2008-09-15 Taisho Pharmaceutical Co Ltd 6-fluorobicyclo 3.1.0 hexan-derivate
WO2003068813A2 (en) 2002-02-11 2003-08-21 Shire Biochem Inc Group b streptococcus antigen
GB2385274B (en) 2002-02-13 2004-04-14 Ming-Jeng Shue Vaginal suppository delivery device
US6593093B1 (en) * 2002-02-20 2003-07-15 Mayo Foundation For Medical Education And Research Detection of group a Streptococcus
WO2003087353A2 (en) 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
US20050181388A1 (en) 2002-04-02 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
WO2004018646A2 (en) 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
WO2004041157A2 (en) 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
TW566366U (en) 2002-09-27 2003-12-11 Wus Tech Co Ltd Labor-saving portable battery equipment for power-driven walking assisted scooter
EP2314603A3 (de) 2002-10-15 2011-05-18 Intercell AG Bindungdsfaktoren von Gruppe B-Streptococcus, dafür kodierende Nukleinsäuren und Verwendungen davon
EP1601770B1 (de) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigene
US20060134640A1 (en) * 2003-04-22 2006-06-22 Institut Pasteur Inhibiting the growth of bacterial biofilms
EP1620460A2 (de) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae-antigene i + ii
US20050016201A1 (en) 2003-07-22 2005-01-27 Ivanov Igor C. Multi-staged heating system for fabricating microelectronic devices
JP4875490B2 (ja) 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
AU2003904237A0 (en) 2003-08-08 2003-08-21 Garvan Institute Of Medical Research Novel translocation assay
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
CA2537742C (en) 2003-09-15 2014-07-22 Chiron Corporation Immunogenic compositions for streptococcus agalactiae
KR101178776B1 (ko) 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CN101056877B (zh) * 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
GB0421465D0 (en) 2004-09-27 2004-10-27 Chiron Srl Group A streptococcus protein
AU2005335216A1 (en) 2004-10-05 2007-02-15 Wyeth Probe arrays for detecting multiple strains of different species
WO2006042027A2 (en) 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2006069200A2 (en) 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI2351772T1 (sl) * 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
JP5219803B2 (ja) 2005-05-13 2013-06-26 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド グラム陽性菌の血清耐性因子
EP1937304A2 (de) * 2005-08-24 2008-07-02 Novartis Vaccines and Diagnostics S.r.l. Zwitterionisation kapselförmiger saccharide
EP1770171A1 (de) 2005-09-29 2007-04-04 Universität Zu Köln DNA-Mikroarray zur schnellen Identifizierung von Candida albicans in Blutkultur.
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
AU2006335256B2 (en) * 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
DK176565B1 (da) 2006-02-03 2008-09-08 Quilts Of Denmark As Möbelben med lys
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
EP2319862A1 (de) 2006-07-07 2011-05-11 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
EP2063911A2 (de) * 2006-07-26 2009-06-03 Novartis Ag Immunogene zusammensetzungen für gram-positive bakterien
AU2007348285A1 (en) 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
CA2699513C (en) * 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
BRPI0821240B8 (pt) * 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o

Also Published As

Publication number Publication date
JP2016026494A (ja) 2016-02-18
US7955604B2 (en) 2011-06-07
JP2010508808A (ja) 2010-03-25
EP1671981A3 (de) 2006-07-05
DE60139563D1 (de) 2009-09-24
US20160264632A1 (en) 2016-09-15
US8431139B2 (en) 2013-04-30
EP2277896A1 (de) 2011-01-26
NZ594877A (en) 2012-07-27
IL202254A (en) 2016-02-29
NZ593617A (en) 2012-04-27
NZ540544A (en) 2007-08-31
HK1153754A1 (en) 2012-04-05
US20150368304A1 (en) 2015-12-24
JP2009118848A (ja) 2009-06-04
IL154853A (en) 2010-06-16
US20060210580A1 (en) 2006-09-21
JP4254931B1 (ja) 2009-04-15
AU2002214127B2 (en) 2007-06-07
WO2002034771A3 (en) 2003-01-16
US8137673B2 (en) 2012-03-20
US10428121B2 (en) 2019-10-01
US20060258849A1 (en) 2006-11-16
CA2425303A1 (en) 2002-05-02
US20060210579A1 (en) 2006-09-21
EP2284181A1 (de) 2011-02-16
EP2277895B1 (de) 2013-08-14
CA2881568A1 (en) 2002-05-02
NZ583028A (en) 2011-10-28
SG165981A1 (en) 2010-11-29
US9738693B2 (en) 2017-08-22
EP2284183A1 (de) 2011-02-16
MXPA03003690A (es) 2004-05-05
JP2011239783A (ja) 2011-12-01
IL238319A0 (en) 2015-06-30
EP1671981A2 (de) 2006-06-21
JP4874323B2 (ja) 2012-02-15
US9840538B2 (en) 2017-12-12
MX357775B (es) 2018-07-20
US20180094033A1 (en) 2018-04-05
EP2284182A1 (de) 2011-02-16
ZA200302739B (en) 2005-01-26
US20130129740A1 (en) 2013-05-23
CY1110698T1 (el) 2015-06-10
EP1328543B1 (de) 2009-08-12
US20100105865A1 (en) 2010-04-29
IL154853A0 (en) 2003-10-31
EP2896629A1 (de) 2015-07-22
NZ524888A (en) 2006-09-29
US20060210582A1 (en) 2006-09-21
NZ560966A (en) 2010-06-25
EP1328543A2 (de) 2003-07-23
ES2330083T3 (es) 2009-12-04
WO2002034771A2 (en) 2002-05-02
JP2013165714A (ja) 2013-08-29
DK1328543T3 (da) 2009-11-23
AU1412702A (en) 2002-05-06
IL264925A (en) 2019-05-30
US20060210581A1 (en) 2006-09-21
EP2189473A3 (de) 2010-08-11
IL238319B (en) 2019-03-31
EP2277894A1 (de) 2011-01-26
EP2277895A1 (de) 2011-01-26
US8025890B2 (en) 2011-09-27
CA2881568C (en) 2019-09-24
US7939087B2 (en) 2011-05-10
EP2189473A2 (de) 2010-05-26

Similar Documents

Publication Publication Date Title
DE60139563D1 (de) Nukleinsäuren und proteine von gruppen a und b-streptokokken
WO2002094868A3 (en) Staphylococcus aureus proteins and nucleic acids
WO2002077021A3 (en) Streptococcus pneumoniae proteins and nucleic acids
WO2003093306A3 (en) Nucleic acids and proteins from streptococcus groups a & b
DE60217320D1 (de) Gonokokkenproteine und nukleinsäuren
NO20020348D0 (no) Peptid acceptor ligeringsmetoder
ATE476508T1 (de) Neisseriale antigene
DK1093517T3 (da) Neisseria-meningitidis-antigener og præparater
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
DK1383903T3 (da) Fremgangsmåder til fremstilling af askorbinsyre-intermediater i vært-celler
DE69732029D1 (de) Dna enthaltende impfstoffen
DE60235223D1 (de) Streptococcus pyogenes polypeptide und entsprechende dna fragmente

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1328543

Country of ref document: EP